Latest Breaking News On - Genitourinary malignancy program - Page 1 : comparemela.com

First-line nivolumab plus cabozantinib continues to show superiority to sunitinib in the treatment of patients with advanced advanced renal cell carcinoma (RCC).

New yorkUnited statesMauricio burottoBenjamina gartrellManuela schmidingerBradford hill clinical research centerAlbert einstein college of medicineRcc database consortiumUniversity of viennaGenitourinary cancers symposiumNew england journalAll endpointsMedical universityGenitourinary malignancy programMontefiore einstein cancer centerAlbert einstein college